Published in Lab Law Weekly, June 10th, 2005
The parties have already started generating fully human antiPD-1 antibody product candidates under Ono's intellectual property regarding PD-1 and using Medarex's proprietary UltiMAb Human Antibody Development System, and they expect that clinical studies could begin in 12 to 24 months.
Under this arrangement, Ono and Medarex will jointly work toward potential commercialization of an antiPD-1 antibody. The two companies plan to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.